Cdk5 Sebagai Target Potensial Penemuan Obat Anti Nyeri Kronik
DOI:
https://doi.org/10.29303/jku.v12i3.968Kata Kunci:
Nyeri kronik, Cdk5, obat penghambat Cdk5Abstrak
Nyeri kronik merupakan suatu kondisi yang sangat mengganggu dan hingga saat ini belum ditemukan obat yang efektif dan aman. Hal ini bisa disebabkan karena obat yang ada belum mengenai target penting dalam transmisi nyeri kronik. Cdk5 adalah protein kinase yang telah terbukti memiliki peran kunci dalam transmisi nyeri kronik. Peran penting tersebut antara lain : pengaktifan TRPV1 ,NMDA, P/Q type voltage- dependent calcium channel, dan reseptor ATP-gate P2X . Cdk5 bisa dijadikan sebagai target potensial dalam pengembangan obat anti nyeri kronik yang baru. Beberapa aspek yang menjadi perhatian dalam pengembangan obat yang mentarget Cdk5 tersebut adalah peran Cdk5 dalam kondisi fisiologis dan patologis karena hal ini akan berhubungan dengan resiko efek samping. faktor lain yang juga sangat perlu dipertimbangkan adalah lokasi ekspresi Cdk5 karena hal ini akan sangat menentukan desain obat. Beberapa obat yang telah dikembangkan sebagai penghambat Cdk5 adalah roscovitin, olomoucine, dan indirubin.
Referensi
Abraham, R. T., Acquarone, M., Andersen, A., Asensi, A., Bellé, R., Berger, F., Bergounioux, C., Brunn, G., Buquet-Fagot, C., & Fagot, D. (1995). Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell, 83(2–3), 105–120. https://doi.org/10.1016/0248-4900(96)81298-6
Allnutt, A. B., Waters, A. K., Kesari, S., & Yenugonda, V. M. (2020). Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease. ACS Chemical Neuroscience, 11(9), 1218–1230. https://doi.org/10.1021/acschemneuro.0c00096
Aobchey, P., Sinchaikul, S., Phutrakul, S., & Chen, S. T. (2007). Simple purification of indirubin from Indigofera tinctoria Linn. and inhibitory effect on MCF-7 human breast cancer cells. Chiang Mai J. Sci., 34(3), 329–337.
Berger, J. M., & Zelman, V. (2016). Pathophysiology of Chronic Pain. Pain Medicine, 1(2 SE-Lecture). https://painmedicine.org.ua/index.php/pnmdcn/article/view/12
Chen, M.-C., Lin, H., Hsu, F.-N., Huang, P.-H., Lee, G.-S., & Wang, P. S. (2010). Involvement of cAMP in nerve growth factor-triggered p35/Cdk5 activation and differentiation in PC12 cells. American Journal of Physiology. Cell Physiology, 299(2), C516-27. https://doi.org/10.1152/ajpcell.00534.2009
Chiker, S., Pennaneach, V., Loew, D., Dingli, F., Biard, D., Cordelières, F. P., Gemble, S., Vacher, S., Bieche, I., Hall, J., & Fernet, M. (2015). Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients. Cell Cycle (Georgetown, Tex.), 14(19), 3066–3078. https://doi.org/10.1080/15384101.2015.1078020
Cicenas, J., Kalyan, K., Sorokinas, A., Stankunas, E., Levy, J., Meskinyte, I., Stankevicius, V., Kaupinis, A., & Valius, M. (2015). Roscovitine in cancer and other diseases. Annals of Translational Medicine, 3(10), 1–12. https://doi.org/10.3978/j.issn.2305-5839.2015.03.61
Cohen, I., & Lema, M. J. (2020). What’s new in chronic pain pathophysiology. Canadian Journal of Pain, 4(4), 13–18. https://doi.org/10.1080/24740527.2020.1752641
Havlíček, L., Hanuš, J., Veselý, J., Leclerc, S., Meijer, L., Shaw, G., & Strnad, M. (1997). Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds. Journal of Medicinal Chemistry, 40(4), 408–412. https://doi.org/10.1021/jm960666x
Kumar Pareek, T. (2012). Cdk5: An Emerging Kinase in Pain Signaling. Brain Disorders & Therapy, 01(s1). https://doi.org/10.4172/2168-975x.s1-003
Kumar, S. K., LaPlant, B., Chng, W. J., Zonder, J., Callander, N., Fonseca, R., Fruth, B., Roy, V., Erlichman, C., & Stewart, A. K. (2015). Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood, 125(3), 443–448. https://doi.org/10.1182/blood-2014-05-573741
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y. Z., Mandelkow, E. M., Eisenbrand, G., & Meijer, L. (2001). Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors? The Journal of Biological Chemistry, 276(1), 251—260. https://doi.org/10.1074/jbc.m002466200
Lin, S. F., Lin, J. Der, Hsueh, C., Chou, T. C., & Wong, R. J. (2017). A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE, 12(2), 1–18. https://doi.org/10.1371/journal.pone.0172315
Liu, J., Yang, J., Xu, Y., Guo, G., Cai, L., Wu, H., Zhao, Y., & Zhang, X. (2017). Roscovitine, a CDK5 Inhibitor, Alleviates Sevoflurane-Induced Cognitive Dysfunction via Regulation Tau/GSK3β and ERK/PPARγ/CREB Signaling. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 44(2), 423–435. https://doi.org/10.1159/000485008
Mills, S. E. E., Nicolson, K. P., & Smith, B. H. (2019). Chronic pain: a review of its epidemiology and associated factors in population-based studies. British Journal of Anaesthesia, 123(2), e273–e283. https://doi.org/10.1016/j.bja.2019.03.023
Muzayyinah. (2014). Indigofera: “Kini dan Nanti.” Bioedukasi: Jurnal Pendidikan Biologi, 7(2), 23. https://doi.org/10.20961/bioedukasi-uns.v7i2.2932
Nemunaitis, J. J., Small, K. A., Kirschmeier, P., Zhang, D., Zhu, Y., Jou, Y. M., Statkevich, P., Yao, S. L., & Bannerji, R. (2013). A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Translational Medicine, 11(1). https://doi.org/10.1186/1479-5876-11-259
Pao, P. C., & Tsai, L. H. (2021). Three decades of Cdk5. Journal of Biomedical Science, 28(1), 1–17. https://doi.org/10.1186/s12929-021-00774-y
Pfänder, P., Fidan, M., Burret, U., Lipinski, L., & Vettorazzi, S. (2019). Cdk5 Deletion Enhances the Anti-inflammatory Potential of GC-Mediated GR Activation During Inflammation. 10(July), 1–13. https://doi.org/10.3389/fimmu.2019.01554
Qorib, M. F., Reny, I., Sudjarwo, S. A., & Basori, A. (2021). The Role of Cdk5 and TRPV1 in Meloxicam Resistance Signal Transduction in Rat Experiencing Chronic Pain. Indian Journal of Forensic Medicine & Toxicology, 15(3), 3775–3784. https://doi.org/10.37506/ijfmt.v15i3.15884
Saqub, H., Proetsch-Gugerbauer, H., Bezrookove, V., Nosrati, M., Vaquero, E. M., de Semir, D., Ice, R. J., McAllister, S., Soroceanu, L., Kashani-Sabet, M., Osorio, R., & Dar, A. A. (2020). Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Scientific Reports, 10(1), 18489. https://doi.org/10.1038/s41598-020-75578-5
Schwan, J., Sclafani, J., & Tawfik, V. L. (2019). Chronic Pain Management in the Elderly. Anesthesiology Clinics, 37(3), 547–560. https://doi.org/10.1016/j.anclin.2019.04.012
Tian, Z., Feng, B., Wang, X.-Q., & Tian, J. (2022). Focusing on cyclin-dependent kinases 5: A potential target for neurological disorders. Frontiers in Molecular Neuroscience, 15, 1030639. https://doi.org/10.3389/fnmol.2022.1030639
Utreras, E., Futatsugi, A., Pareek, T. K., & Kulkarni, A. B. (2009). Molecular roles of Cdk5 in pain signaling. In Drug Discovery Today: Therapeutic Strategies (Vol. 6, Issue 3, pp. 105–111). Elsevier Ltd. https://doi.org/10.1016/j.ddstr.2009.04.004
Wahyuningsih, S., Ramelan, A. H., Wardani, D. K., Aini, F. N., Sari, P. L., Tamtama, B. P. N., & Kristiawan, Y. R. (2017). Indigo Dye Derived from Indigofera Tinctoria as Natural Food Colorant. IOP Conference Series: Materials Science and Engineering, 193(1). https://doi.org/10.1088/1757-899X/193/1/012048
Xing, B. M., Yang, Y. R., Du, J. X., Chen, H. J., Qi, C., Huang, Z. H., Zhang, Y., & Wang, Y. (2012). Cyclin-dependent kinase 5 controls TRPV1 membrane trafficking and the heat sensitivity of nociceptors through KIF13B. Journal of Neuroscience, 32(42), 14709–14721. https://doi.org/10.1523/JNEUROSCI.1634-12.2012
Zheng, Y.-L., Zhang, X., Fu, H.-X., Guo, M., Shukla, V., Amin, N. D., E, J., Bao, L., Luo, H.-Y., Li, B., Lu, X.-H., & Gao, Y.-C. (2016). Knockdown of Expression of Cdk5 or p35 (a Cdk5 Activator) Results in Podocyte Apoptosis. PloS One, 11(8), e0160252. https://doi.org/10.1371/journal.pone.0160252
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Unram Medical Journal
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
